Triple Inhaler Therapy for Early Lung Function Problems
Part of Lungs & breathing clinical trials.
This study tests a combination inhaler medicine in people with early signs of lung function decline and a smoking history. The goal is to see if this three-drug combination can help improve breathing and prevent further lung damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–75 years
- Smoking history of at least 10 pack-years (roughly 1 pack per day for 10 years, or equivalent)
- Lung function test results showing early impairment (FEV1/FVC between 0.7–0.8, and FEV1 less than 80% predicted)
- At least one ongoing breathing symptom like cough, phlegm, or shortness of breath for 3+ months
- Ability to use an inhaler correctly and attend follow-up visits for 12 weeks
- No diagnosis of asthma, COPD, bronchiectasis, or other serious lung or heart conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if exercise can help smokers or former smokers who have early signs of lung trouble (called PRISm) and may later develop COPD. Participation involves exercise and monitoring to see if it can slow or prevent lung disease.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This trial is testing a combination of three inhaled medicines (triple therapy) to see how well they help the small airways in people whose lung disease is caused by breathing in smoke from cooking or heating with wood or other biomass fuels. It may be a good fit if you have COPD or chronic bronchitis from this type of exposure.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This study tests a fixed triple combination inhaler (Trimbow) for people whose asthma is not well controlled with their current treatment. It looks at how well this inhaler works in everyday life over time.
Hear when a new Preserved Ratio Impaired Spirometry (PRISM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.